Extracts of Sideritis scardica as triple monoamine reuptake inhibitors

Knörle, Rainer
December 2012
Journal of Neural Transmission;Dec2012, Vol. 119 Issue 12, p1477
Academic Journal
Sideritis species are traditionally used within the Mediterranean area as teas, flavouring agents or for therapeutical purposes. The aim of this study was to investigate the effects of Sideritis scardica extracts on the monoamine transporters and to derive and explain possible medicinal applications from the pharmacological profile of the extracts. We have studied the effect of various S. scardica extracts on serotonin, noradrenaline and dopamine uptake in rat brain synaptosomes and serotonin uptake in human JAR cells. All extracts inhibited the uptake of all three monoamines into rat brain synaptosomes by their respective transporters, the alcoholic extracts being more effective than the water extract. EC values were in the range of 30-40 μg/ml. Inhibition of the human serotonin transporter by the methanol extract was even more effective (EC 1.4 μg/ml). Combining Sideritis ethanol extract and fluvoxamine resulted in a leftward shift of the fluvoxamine concentration-response curve. The pharmacological profile of S. scardica extracts as triple monoamine reuptake inhibitors suggests their use in the phytochemical therapy of mental disorders associated with a malfunctioning monoaminergic neurotransmission, such as anxiety disorders, major depression, attention-deficit hyperactivity disorder, mental impairment or neurodegenerative diseases.


Related Articles

  • Synaptic Plasticity and NO-cGMP-PKG Signaling Regulate Pre- and Postsynaptic Alterations at Rat Lateral Amygdala Synapses Following Fear Conditioning. Ota, Kristie T.; Monsey, Melissa S.; Wu, Melissa S.; Schafe, Glenn E. // PLoS ONE;2010, Vol. 5 Issue 6, p1 

    In vertebrate models of synaptic plasticity, signaling via the putative ''retrograde messenger'' nitric oxide (NO) has been hypothesized to serve as a critical link between functional and structural alterations at pre- and postsynaptic sites. In the present study, we show that auditory Pavlovian...

  • The Predictive Value of the Dexamethasone Suppression Test A Placebo-Controlled Study. Peselow, Eric O.; Stanley, Michael; Filippi, Ann-Marie; Barouche, Faouzia; Goodnick, Paul; Fieve, Ronald R. // British Journal of Psychiatry;Nov89, Vol. 155, p667 

    We evaluated the dexamethasone suppression test (OST) as a predictor of response to drugs and placebo in 105 patients, in a large double-blind placebo-controlled out-patient trial to determine the efficacy of paroxetine HCI, a selective serotonin reuptake inhibitor, compared with that of...

  • Triple Reuptake Inhibitors: The Next Generation of Antidepressants. Marks, David M.; Chi-Un Pae; Patkar, Ashwin A. // Current Neuropharmacology;Dec2008, Vol. 6 Issue 4, p338 

    Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Current drug development efforts are aimed...

  • Los antidepresivos inhibidores selectivos de recaptura de serotonina (ISRS, ISR-5HT). Chávez- León, Enrique; Patricia Ontiveros Uribe, Martha; Serrano Gómez, Carlos // Salud Mental;jul/ago2008, Vol. 31 Issue 4, p307 

    Depression is a frequent mental disorder in the general population. Approximately 3.7% of the population will suffer a major depressive episode throughout life. Pharmacological treatment with selective serotonin receptor inhibitors (SSRIs) is useful to treat this condition and other mental...

  • Inactivation of 5-HT2C Receptors Potentiates Consequences of Serotonin Reuptake Blockade. Cremers, Thomas I.F.H.; Giorgetti, Marco; Bosker, Fokko J.; Hogg, Sandra; Arnt, Jørn; Mørk, Arne; Honig, Gerard; Bøgesø, Klaus-Peter; Westerink, Ben H.C.; den Boer, Hans; Wikstrom, Håkan V.; Tecott, Laurence H. // Neuropsychopharmacology;Oct2004, Vol. 29 Issue 10, p1782 

    The enhancement of central serotonin system function underlies the therapeutic effects of selective serotonin reuptake inhibitors (SSRIs), which have become the most commonly used class of antidepressant agents. However, many individuals experience depressive episodes that are resistant to SSRI...

  • The Role of Structure Activity Relationship Studies in the Search for New GABA Uptake Inhibitors. Kulig, Katarzyna; Szwaczkiewicz, Marta // Mini Reviews in Medicinal Chemistry;Oct2008, Vol. 8 Issue 12, p1214 

    γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian central nervous system (CNS). A decrease in GABAergic neurotransmission seems to be involved in neurological pathologies such as epilepsy, anxiety and pain. This review is focus on structure activity...

  • KATP Channel Openers Facilitate Glutamate Uptake by GluTs in Rat Primary Cultured Astrocytes. Xiu-Lan Sun; Xiao-Ning Zeng; Fang Zhou; Cui-Ping Dai; Jian-Hua Ding; Gang Hu // Neuropsychopharmacology;Jun2008, Vol. 33 Issue 7, p1336 

    Increasing evidence, including from our laboratory, has revealed that opening of ATP sensitive potassium channels (KATP channels) plays the neuronal protective roles both in vivo and in vitro. Thus KATP channel openers (KCOs) have been proposed as potential neuroprotectants. Our previous studies...

  • Reuptake Transporter.  // Encyclopedic Reference of Molecular Pharmacology;2004, p825 

    The article presents an encyclopedia entry for reuptake transporter. It refers to structures in the cell membranes of the pre-synaptic nerve terminal. The structures are the transporter of biogenic amines from vesicles into the nerve cell. Antideppressants can block reuptake transporters thus...

  • Norepinephrine Transporter Inhibitors from Polygala tenuifolia. Yun-Lian Lin; Wan-Ping Chen; Han-Chieh K0; Feng-Nien Ko; Tian-Shung Wu // Journal of Food & Drug Analysis;Jun2008, Vol. 16 Issue 3, p26 

    Using norepinephrine transporter binding assay-directed fractionation, polygalasaponin XXVIII (1) and 3-O-β-D-glucopyranosyl presenegenin 28-[2 O-β-D-galatopyranosly(1→4)-β-D-xyloparanosyl-(1→4)-α-L-rhamnopyranosyl(1→2)-β-D-fucopyranosyl], together with five...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics